EA
HAE icon

Emerald Acquisition’s Haemonetics HAE Stock Holding History

Emerald Acquisition’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.17M Sell
32,396
-79,586
-71% -$2.73M ﹤0.01% 2036
2016
Q2 		$3.25M Buy
+111,982
New +$3.38M 0.01% 1594

Other funds holding HAE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return

Emerald Acquisition's HAE Position: Q3 2016 in Review

Emerald Acquisition reduced its Haemonetics (HAE) stake by 71% in Q3 2016, selling an estimated $2.73M and leaving 32,396 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2036.

Emerald Acquisition first reported a position in HAE in Q2 2016 and has held it in 2 quarters since. The position peaked at $3.25M in Q2 2016. 180 funds tracked by Wall St. Rank hold HAE as of Q3 2016.

  • Emerald Acquisition held 32,396 shares of Haemonetics worth $1.17M as of Q3 2016.
  • Emerald Acquisition sold 79,586 Haemonetics shares in Q3 2016, an estimated $2.73M.
  • Haemonetics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2036 holding.
  • Emerald Acquisition first reported a position in Haemonetics in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Haemonetics position peaked at $3.25M in Q2 2016.
  • 180 funds tracked by Wall St. Rank held Haemonetics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.